These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 13921051)

  • 21. Effects of ethyl chlorophenoxyisobutyrate on thyroxine distribution, transport and metabolism in man.
    Musa BU; Ogilvie JT; Dowling JT
    Metabolism; 1968 Oct; 17(10):909-15. PubMed ID: 4971141
    [No Abstract]   [Full Text] [Related]  

  • 22. Lipid lowering influence of ethyl p-chlorophenoxyisobutyrate in liver of rats fed high fat diets.
    Kokatnur MG; Malcom GT
    Metabolism; 1970 Feb; 19(2):120-8. PubMed ID: 5410942
    [No Abstract]   [Full Text] [Related]  

  • 23. [Modes and levels of action of clofibrate].
    Thorp JM
    Rev Atheroscler (Paris); 1966; 8(1):2-11. PubMed ID: 5960552
    [No Abstract]   [Full Text] [Related]  

  • 24. [THE ACTION OF CLOFIBRATE-ANDROSTERONE ON THE PLASMA CHOLESTEROL AND LIPIDS].
    VASTESAEGER M; GILLOT P; DELCOURT R
    Brux Med; 1964 Aug; 44():357-75. PubMed ID: 14196801
    [No Abstract]   [Full Text] [Related]  

  • 25. REDUCTION OF CHOLESTEROL AND LIPIDS IN MAN BY ETHYL P-CHLOROPHENOXYISOBUTYRATE.
    HELLMAN L; ZUMOFF B; KESSLER G; KARA E; RUBIN IL; ROSENFELD RS
    Ann Intern Med; 1963 Oct; 59():477-94. PubMed ID: 14067470
    [No Abstract]   [Full Text] [Related]  

  • 26. [BEHAVIOR OF SERUM LIPIDS AND LIPOPROTEINS WITH ADMINISTRATION OF REGELAN (ETHYL-P-CHLOROPHENOXYISOBUTYRATE)].
    KNUECHEL F
    Med Welt; 1964 Nov; 47():2530-6. PubMed ID: 14319572
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] lipid metabolism. II. Effects on the incorporation of various isotopic precursors in rat liver].
    Priego JG; Maroto ML; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):28-30. PubMed ID: 697397
    [No Abstract]   [Full Text] [Related]  

  • 28. Newer hypolipidemic agents.
    Kritchevsky D
    Fed Proc; 1971; 30(3):835-40. PubMed ID: 4996475
    [No Abstract]   [Full Text] [Related]  

  • 29. Antilipaemic drugs and nephrotic hyperlipidaemia.
    Edwards KD
    Prog Biochem Pharmacol; 1972; 7():370-426. PubMed ID: 4567423
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of lipid synthesis by alpha-phenyl-N-butyrate and related compounds.
    STEINBERG D; FREDRICKSON DS
    Proc Soc Exp Biol Med; 1955 Oct; 90(1):232-6. PubMed ID: 13273407
    [No Abstract]   [Full Text] [Related]  

  • 31. [RELATIONS BETWEEN HYPOCHOLESTEREMIC DRUGS AND LIPID METABOLISM: ACTION OF BETA-BENZALBUTYRRAMIDE ON DYSLIPIDEMIA IN RATS FED A LOW-PROTEIN DIET].
    SANGUINETTI F; ZANNONI ML
    Minerva Med; 1963 Oct; 54():2925-9. PubMed ID: 14105485
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of clofibrate on serum and hepatic lipids in nephrotic rats.
    Hoak JC; Connor WE; Armstrong ML; Warner ED
    Lab Invest; 1968 Oct; 19(4):370-5. PubMed ID: 5699117
    [No Abstract]   [Full Text] [Related]  

  • 33. [Action of ethyl chlorophenoxyisobutyrate (CPIB) on blood lipids].
    Giannini SD; da Silva WN; Luthold WW; Coelho LT; Bitelli T
    Rev Bras Med; 1965 Nov; 22(11):702-7. PubMed ID: 5892979
    [No Abstract]   [Full Text] [Related]  

  • 34. [Congenital defects of lipid metabolism. Effect of clofibrate on the level of blood lipids].
    Sobra J
    Cas Lek Cesk; 1969 Nov; 108(48):1439-46. PubMed ID: 4901245
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolic effects of clofibrate on experimental animals.
    Bedö M; Kramer M; Blaskovits A; Gefferth G; Tarjan R
    Arzneimittelforschung; 1978; 28(7):1076-80. PubMed ID: 582692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EFFECT OF CLOFIBRATE AND ANDROSTERONE ON HYPERCHOLESTEROLAEMIC XANTHOMATOSIS.
    MASON B; PERRY CB
    Br Med J; 1965 Jan; 1(5427):102-3. PubMed ID: 14218460
    [No Abstract]   [Full Text] [Related]  

  • 37. Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB).
    Svoboda DJ; Azarnoff DL
    J Cell Biol; 1966 Aug; 30(2):442-50. PubMed ID: 5968981
    [No Abstract]   [Full Text] [Related]  

  • 38. Clofibrate inhibits lipid synthesis and ACTH-stimulated steroidogenesis by rat adrenal tissue.
    Saffran J; Saffran M; Salhanick HA
    Endocrinology; 1970 Mar; 86(3):652-5. PubMed ID: 4312114
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of administration of clofibrate and clofenapate on the content and distribution of ubiquinone in rat tissues.
    Krishnakantha TP; Kurup CK
    Indian J Biochem Biophys; 1974 Mar; 11(1):51-3. PubMed ID: 4435808
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effectof carbamyl-dibenzo-azepine and ethyl parachlorophenoxyisobutyrate on urinary excretion of water and solutes in pitressin-deficient diabetes insipidus].
    Novarini A; Bruschi G; Coruzzi P; Montanari A; Rossi E; Borghetti A
    Minerva Nefrol; 1975; 22(2-3):148-54. PubMed ID: 1226250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.